Blog Posts

Jul 10, 2024, 02:42

Charlotte Davison: Myricx Bio has joined the British Patient Capital portfolio

Charlotte Davison, Board Observer at

“Absolutely thrilled to share that Myricx Bio has joined the British Patient Capital portfolio. We are delighted to have participated in this £90m Series A funding to accelerate development of their novel NMTi ADC platform towards clinic.

It’s been a pleaseure to work with Novo Holdings, Abingworth, Eli Lilly and Company, Sofinnova Partners and Brandon Capital along with a stellar team (Robin Carr, Julie Mead, Francesca Zammarchi) to pull this round together.

Congratulations all! ”

Read further.
Source: Charlotte Davison/LinkedIn

Abingworth Brandon Capital British Patient Capital cancer Charlotte Davison Eli Lilly Francesca Zammarchi Julie Mead Myricx Bio Novo Holdings OncoDaily Oncology Robin Carr Sofinnova Partners

Padraic O’Malley: Meet the Experts of VIRO 2025

Hidden Risks: BRCA Mutations and Breast Implants - CancerWorld

FDA Breakthrough Therapy Designation for Iza-bren: Advancing Treatment for EGFR-Mutant NSCLC

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen